(1)Messori A. Updating Efficacy of First-Line Treatments for Chronic Lymphocytic Leukemia: Indirect Comparisons Based on Recent Data Favor the Combination of Acalabrutinib Plus Obinutuzumab. Eur J Haematol. 2026 Mar 2. doi: 10.1111/ejh.70150. Epub ahead of print. PMID: 41771158.
(2)Messori A, Beltramini S, Crosasso P, Fruttero C, Rivano M, Chiumente M, Silvani MC. Use of artificial intelligence to draft a mini-HTA report on a new medical device belonging to class IIb–III. Glob Reg Health Technol Assess 2026; 13: 55-57ISSN 2283-5733 | DOI: 10.33393/grhta.2026.3691.
(3)Messori A, Brunoro R, Paoli`, M, Rivano M. Sotatercept Versus Selexipag in Severe Pulmonary Arterial Hypertension: An Indirect Comparison of Efficacy Based on an Artificial-Intelligence Method That Reconstructed Patient-Level Data From Three Randomized Trials. Cureus 18(2): e103912. doi:10.7759/cureus.103912, published Feb.19 2026, url https://www.cureus.com/articles/467432-sotatercept-versus-selexipag-in-severe-pulmonary-arterial-hypertension-an-indirect-comparison-of-efficacy-based-on-an-artificial-intelligence-method-that-reconstructed-patient-level-data-from-three-randomized-trials#!/
(4)Messori A. Updating efficacy of first-line treatments for chronic lymphocytic leukemia: indirect comparisons based on recent data favor the combination of acalabrutinib plus obinutuzumab (Letter). *Eur J Hematol.* 2026 (in press), DOI 10.1111/ejh.70150, accepted manuscript available at url http://www.osservatorioinnovazione.net/ejh-accepted-paper.pdf
(5)Messori A, Beltramini S, Crosasso P, Fruttero C, Rivano M, Chiumente M, Silvani MC. Use Of Artificial Intelligence To Draft A Mini-HTA Report On A New Medical Device Belonging To Class IIb-III. Global and Regional Health TEchnology Assessment, 2026 (in press), accepted manuscript available at url http://www.osservatorioinnovazione.net/grhta2026.pdf
(6)Messori A, Ossato A, Gasperoni L, Del Bono L, Inno A, Damuzzo V. Treatment Options for Advanced Non-Small Cell Lung Cancer After Failure of Previous Immune Checkpoint Inhibitors and Chemotherapy: Meta-Analysis of Five Randomized Controlled Trials. Curr Oncol. 2025 Jan 17;32(1):46. doi: 10.3390/curroncol32010046. PMID: 39851962; PMCID: PMC11763427.
(7)Piragine E, Veneziano S, Trippoli S, Messori A, Calderone V. Efficacy and Safety of Cardioband in Patients with Tricuspid Regurgitation: Systematic Review and Meta-Analysis of Single-Arm Trials and Observational Studies. J Clin Med. 2024 Oct 25;13(21):6393. doi: 10.3390/jcm13216393. PMID: 39518532; PMCID: PMC11546409.
(8)Messori A, Trippoli S. Treatment of Patients With De Novo Small-Vessel Coronary Lesions: Analysis of Six Randomised Controlled Trials Comparing Paclitaxel-Coated Balloons With Drug-Eluting Stents. Cureus. 2024 Sep 23;16(9):e69983. doi: 10.7759/cureus.69983. PMID: 39315315; PMCID: PMC11418083.
(9)Messori A, Romeo MR, Rivano M, Trippoli S. Real-world data on the effectiveness of TYRX and TauroPace for preventing CIED infections. Am J Cardiovasc Dis. 2024 Aug 25;14(4):220-229. doi: 10.62347/DSHG1684. PMID: 39309111; PMCID: PMC11410787.
(10) Messori A, Trippoli S, Romeo MR, Fadda V, Rivano M, Spazio LD. Studying the Outcomes in Patients with Tricuspid Regurgitation Treated with Valve Repair or Valve Replacement: Interpreting the Survival Pattern on The Long Term by Application of Artificial Intelligence Methods. Rev Cardiovasc Med. 2024 Jun 20;25(6):223. doi: 10.31083/j.rcm2506223. PMID: 39076326; PMCID: PMC11270104.
(11) Messori A. Sacituzumab govitecan for metastatic breast cancer: the TROPiCS-02 trial. Lancet. 2024 Jul 27;404(10450):338-339. doi: 10.1016/S0140-6736(24)01047-X. PMID: 39067900.
(12) Rivano M, Cancanelli L, Brunoro R, Fasano Celentano CN, Di Spazio L, Mengato D, Messori A. Radiofrequency Ablation, Cryotherapy Ablation, or Pulsed-Field Ablation to Treat Paroxysmal Atrial Fibrillation Unresponsive to Pharmacological Treatments: Interpreting Efficacy Through Reconstruction of Individual Patient Data From Randomized Trials. Cureus. 2024 Jul 22;16(7):e65113. doi: 10.7759/cureus.65113. PMID: 39040611; PMCID: PMC11262592.
(13) Messori A, Trippoli S, Fadda V. Transcatheter Versus Surgical Aortic Valve Replacement in Patients at Low Risk: Long-Term Outcomes From the Three Pivotal Randomised Trials Determined by Reconstruction of Individual Patient Data From Kaplan-Meier Curves. Heart Lung Circ. 2024 Jul;33(7):e38-e40. doi: 10.1016/j.hlc.2023.12.023. PMID: 39032976.
(14) Gasperoni L, Del Bono L, Ossato A, Giunta EF, Messori A, Damuzzo V. A Head- to-Head Comparison of the First-Line Treatments for Locally Advanced or Metastatic Urothelial Cancer: Is There Still a Role for Chemotherapy? Cancers (Basel). 2024 Jun 29;16(13):2400. doi: 10.3390/cancers16132400. PMID: 39001462; PMCID: PMC11240305.
(15) Messori A, Trippoli S. Study of CardioMEMS in heart failure patients: Study confirms benefit in costs and quality-adjusted life years, but does not measure quality-adjusted life years. ESC Heart Fail. 2024 Dec;11(6):4437. doi: 10.1002/ehf2.14960. Epub 2024 Jul 2. PMID: 38953112; PMCID: PMC11631278.
(16) Messori A, Romeo MR, Trippoli S. Remote Monitoring in Heart Failure: Inclusion of Different Studies in the Same Meta-Analysis. J Am Coll Cardiol. 2024 Jun 11;83(23):e231. doi: 10.1016/j.jacc.2024.02.058. PMID: 38839208.

(17) Gasperoni L, Cancanelli L, Ossato A, Del Bono L, Vecchia S, Fontanella C, Damuzzo V, Messori A. Comparative Analysis of Maintenance Treatments in Patients with Newly Diagnosed Advanced Ovarian Cancer After First-Line Platinum-Based Regimens. Cancers (Basel). 2025 Nov 20;17(22):3714. doi: 10.3390/cancers17223714. PMID: 41301076; PMCID: PMC12651439
(18) Veneziano S, Trippoli S, Messori A, Calderone V, Piragine E. Transcatheter Tricuspid Valve Interventions to Manage Tricuspid Regurgitation: A Narrative Review. Rev Cardiovasc Med. 2025 Aug 15;26(8):39915. doi: 10.31083/RCM39915. PMID: 40927111; PMCID: PMC12415768.
(19) Messori A, Tognarelli B, Monzillo J, Trippoli S. Simplified Algorithm for Determining Value-Based Pricing of High-Tech Medical Devices in the Tuscany Region of Italy. Cureus. 2025 Jun 25;17(6):e86743. doi: 10.7759/cureus.86743. PMID: 40574939; PMCID: PMC12198941.
(20) Damuzzo V, Gasperoni L, Del Bono L, Ossato A, Inno A, Messori A. Treatment of metastatic ALK-positive non-small cell lung cancer: indirect comparison of different ALK inhibitors using reconstructed patient data. Front Oncol. 2025 May 9;15:1566816. doi: 10.3389/fonc.2025.1566816. PMID: 40416880; PMCID: PMC12098575.
(21) Messori A, Potocnik M, Belazregue S, Collins R, Krämer T, Chadwick FM. PCP and POCOP complexes of calcium. Chem Commun (Camb). 2025 May 22;61(43):7827-7830. doi: 10.1039/d5cc00872g. PMID: 40310987.
(22) Brunoro R, Di Spazio L, Rivano M, Cancanelli L, Celentano CNF, Mengato D, Messori A. Radiofrequency or cryoablation or medical therapy for paroxysmal atrial fibrillation: An indirect comparison of effectiveness. J Arrhythm. 2025 Apr 1;41(2):e70054. doi: 10.1002/joa3.70054. PMID: 40171186; PMCID: PMC11960708.
(23) Trippoli S, Messori A. Transcatheter Valve Replacement in Severe Tricuspid Regurgitation. N Engl J Med. 2025 Mar 27;392(12):1244. doi: 10.1056/NEJMc2501560. PMID: 40138565.
(24) Piragine E, Trippoli S, Veneziano S, Messori A, Calderone V. The Reconstructed Individual Patient Data from Kaplan-Meier (IPDfromKM) Method for Non-Inferiority Analyses: A New Potential Application. Methods Protoc. 2025 Feb 2;8(1):13. doi: 10.3390/mps8010013. PMID: 39997637; PMCID: PMC11857869.
(25) Messori A, Trippoli S, Piragine E, Veneziano S, Calderone V. A Meta-Analysis of First-Line Treatments for Unresectable Pleural Mesothelioma: Indirect Comparisons from Reconstructed Individual Patient Data of Six Randomized Controlled Trials. Cancers (Basel). 2025 Feb 3;17(3):503. doi: 10.3390/cancers17030503. PMID: 39941870; PMCID: PMC11815993.
(26) Messori A, Trippoli S. Medical Devices in the Region of Tuscany, Italy: Definitions of Innovative Devices and Potentially Innovative Devices and Their Impact on Procurement Decisions. Cureus. 2024 Dec 16;16(12):e75839. doi: 10.7759/cureus.75839. PMID: 39698198; PMCID: PMC11654317.